Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
RNA
Strong SellSinkerAtrium Therapeutics, Inc. · Healthcare · United States · $233M · Avg Vol: $2M/d
COMPANY DESCRIPTION
Atrium Therapeutics, Inc. is a biotechnology company dedicated to developing novel RNA-targeted therapeutics for rare and severe diseases. The company leverages its proprietary RNA delivery platform to target previously undruggable genetic pathways, establishing a strong intellectual property moat. It operates as an innovative clinical-stage player in the high-growth genetic medicine sector.
FINANCIAL SUMMARY (USD)
| Year | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9.8M | 10.9M | 18.6M | 38.1% | 35.8M | 34.4M | — | 84.6% |
| EPS | -0.37 | -1.47 | -2.89 | — | -5.44 | -4.55 | -8.06 | — |
| Shares | 17.1M | 17.1M | 17.1M | 0.0% | 17.1M | — | — | — |
| Debt | 9.9M | 6.8M | 3.7M | -38.9% | 1.7M | — | — | — |
| Equity | -70.6M | -61.1M | 207.3M | — | — | — | — | — |
| Op CF | 56.4M | -22.6M | -41.1M | — | -53.2M | — | — | — |
| Inv CF | -0.3M | -0.3M | -1.4M | — | — | — | — | — |
| Fin CF | -56.1M | 22.8M | 42.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RNA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RNA | Atrium Therapeutics, Inc.(you) | $233M | 11 | Strong Sell |
| NERV | Minerva Neurosciences, Inc. | $231M | 11 | Strong Sell |
| TARA | Protara Therapeutics, Inc. | $226M | 9 | Strong Sell |
| NBP | NovaBridge Biosciences | $213M | 10 | Strong Sell |
| CHRS | Coherus Oncology, Inc. | $218M | 13 | Strong Sell |
| TRDA | Entrada Therapeutics, Inc. | $273M | 10 | Strong Sell |
| CAMP | CAMP4 THERAPEUTICS CORPORATION | $260M | 9 | Strong Sell |
| TNXP | Tonix Pharmaceuticals Holding Corp. | $233M | 15 | Strong Sell |
| ABOS | Acumen Pharmaceuticals, Inc. | $211M | 13 | Strong Sell |
| SRZN | Surrozen, Inc. | $264M | 9 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%